For the fiscal year ending March 2026, net sales are 41,899 million yen (up 3.4% YoY), operating profit is 2,919 million yen (down 2.7% YoY), and net income attributable to owners of parent is 3,708 million yen (up 66.5% YoY). For the fiscal year ending March 2027, sales are projected to be 42 billion yen, operating profit 3,007 million yen, and net income attributable to owners of parent 2,070 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4549","jir_company_name":"Eiken Chemical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4549-20260512-02.pdf","jir_short_summary":"For the fiscal year ending March 2026, net sales are 41,899 million yen (up 3.4% YoY), operating profit is 2,919 million yen (down 2.7% YoY), and net income attributable to owners of parent is 3,708 million yen (up 66.5% YoY). For the fiscal year ending March 2027, sales are projected to be 42 billion yen, operating profit 3,007 million yen, and net income attributable to owners of parent 2,070 million yen.","jir_summary":"### Fiscal Year 2026 Financial Results Overview\nNet sales for the fiscal year ending March 2026 reached 41,899 million yen (up 3.4% YoY), mainly driven by substantial growth in overseas hematuria test reagent and medical device sales. Operating profit was 2,919 million yen (down 2.7% YoY), due to changes in sales composition leading to decrease, but profit increased to 3,708 million yen (up 66.5% YoY) supported by gains from the transfer of equity interests of consolidated subsidiaries. Segment-wise, domestic and international hematuria test sales rose, as did medical devices, while microbial, instruments & food environment, and genetic-related segments decreased.\n\n### Forecast for FY2027 and Reassessment of the FY2030 Management Plan\nThe full-year forecast for FY2027 projects net sales of 42 billion yen (up 0.2% YoY), operating profit of 3,007 million yen (up 5.2% YoY), and net income attributable to owners of parent of 2,070 million yen (down 44.2% YoY). The company expects to achieve increase in revenue and profit, with domestic sales mainly driven by core products and overseas sales reaching 95.1% of the budget despite the closure of USAID. Additionally, the FY2030 management plan (FY2026-FY2030) will be restructured as a mid-term plan, emphasizing ROIC management, improving capital efficiency and profitability. Organizational and cultural reforms, strengthening markets and brands, and establishing systems for growth investments and M&A will be advanced.","jir_financial_highlights":"Net Sales: 41,899 million yen (Up 3.4% YoY)\nOperating Profit: 2,919 million yen (Down 2.7% YoY)\nOrdinary Income: 2,844 million yen (Down 11.1% YoY)\nNet Income Attributable to Owners of Parent: 3,708 million yen (Up 66.5% YoY)\nForecast for FY2027 Net Sales: 42 billion yen (Up 0.2% YoY)\nForecast for FY2027 Operating Profit: 3,007 million yen (Up 5.2% YoY)\nForecast for FY2027 Net Income attributable to owners of parent: 2,070 million yen (Down 44.2% YoY)\nDividend per share: 58 yen (Unknown)","jir_category":"","jir_hashtags":"#EikenChemical, #FinancialResults, #ManagementPlan","jir_key_figures":"Net Sales: 41,899 million yen (up 3.4% YoY)\nOperating Profit: 2,919 million yen (down 2.7% YoY)\nNet Income Attributable to Owners of Parent: 3,708 million yen (up 66.5% YoY)","jir_meta_title":"\u3010Eiken Chemical\u3011FY2026 Financial Results\uff5cNet Sales 41.8 Billion Yen (+3.4% YoY)","jir_meta_description":"Eiken Chemical Co., Ltd. announced FY2026 financial results. Net sales reached 41,899 million yen (up 3.4%), net income attributable to owners of parent was 3,708 million yen (up 66.5%). For FY2027, sales are forecasted at 42 billion yen.","jir_og_title":"\u3010Eiken Chemical\u3011FY2026 Financial Results\uff5cNet Sales 41.8 Billion Yen (+3.4%)","jir_og_description":"FY2026 financial results announcement. Net sales exceeded 41 billion yen, net income over 3.7 billion yen. Revenue is expected to increase in FY2027.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[40539,41899],\\\"backgroundColor\\\":\\\"#007bff\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Profit Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit\\\",\\\"data\\\":[2999,2919],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025\\\",\\\"FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[2228,3708],\\\"backgroundColor\\\":\\\"#dc3545\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment-wise Net Sales (FY2026, Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Hematuria\\\",\\\"Immunoserology (excluding Hematuria)\\\",\\\"Urinalysis\\\",\\\"Microbial\\\",\\\"Biochemistry\\\",\\\"Instruments & Food Environment\\\",\\\"Genetic-related\\\",\\\"Medical Devices & Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[13470,9816,4623,4284,579,1818,1957,5348],\\\"backgroundColor\\\":\\\"#17a2b8\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"region_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Regional Net Sales (FY2026, Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic\\\",\\\"Overseas\\\",\\\"Americas\\\",\\\"EMEA\\\",\\\"APAC\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[30442,11457,2516,4774,4165],\\\"backgroundColor\\\":\\\"#ffc107\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":16754,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-46886","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n